Northway Biotech
24.5.2023 18:24:40 CEST | ACCESS Newswire | Press release
WALTHAM, MA / ACCESSWIRE / May 24, 2023 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.
Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."
To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.
About Northway Biotech - https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.
For Further Information, Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/757061/Northway-Biotech-Set-to-Launch-Advanced-Microbial-and-Mammalian-GMP-Facilities-in-Massachusetts
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses28.4.2026 16:00:00 CEST | Press release
TruMerit 2025 Nurse Migration Report reveals workforce inequities widening across regions. PHILADELPHIA, PA / ACCESS Newswire / April 28, 2026 / TruMerit™ (formerly CGFNS International) today released its 2025 Nurse Migration Report, revealing significant shifts in global nurse migration patterns and widening inequities in nursing workforce distribution across regions with vastly different healthcare needs. The report, which analyzes World Health Organization data and TruMerit's proprietary VisaScreen® application records, shows that international nurse migration flows are increasingly concentrated in regions with stronger healthcare infrastructure, while areas facing severe nursing shortages continue to lose ground in their ability to employ internationally educated nurses. Europe and Southeast Asia see sharp increases in international nurse employment. According to TruMerit's analysis of WHO nursing workforce data, Europe now employs internationally educated nurses at a rate represen
Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture28.4.2026 15:00:00 CEST | Press release
Tenstorrent GalaxyTM Blackhole delivers general-purpose AI with native scale-out for winning performance in AI video generation and LLMs - prefill and decode. SANTA CLARA, CA / ACCESS Newswire / April 28, 2026 / Tenstorrent, the AI compute company led by CEO, Jim Keller, announces today general availability of Tenstorrent Galaxy Blackhole deployed at scale, delivering industry-leading general-purpose AI performance. Other solutions require bolting together separate accelerators across fragmented infrastructure. Tenstorrent's Networked AI delivers them natively - compute, memory, and networking unified into a single system optimized for real-world AI workloads. Leading Industry Performance, Affordable Prices General-purpose means leading performance on every workload defining modern AI, not specializing in one. Tenstorrent Galaxy tops video generation, large-context LLM inference in both prefill and decode, and the full range of model architectures shipping today. See it for yourself on
Kontent.ai Appoints Mark Greenaway as CEO to Drive the Next Phase of AI in Enterprise Content27.4.2026 08:00:00 CEST | Press release
BRNO, CZ / ACCESS Newswire / April 27, 2026 / Kontent.ai has appointed Mark Greenaway as Chief Executive Officer, as the company looks to scale its Agentic CMS and transform content operations for customers. Greenaway brings a track record of scaling businesses and leading high performing global teams with a focus on enterprise environments where content is both a marketing asset and a critical driver of growth, compliance, and customer experience. With this appointment, Kontent.ai founder Petr Palas returns to his position on the board at Kontent.ai and will continue to support the business he launched in 2022 as a successful spin out of Kentico. Kontent.ai recently launched their next generation of "Agentic CMS" with the launch of Expert Agents. These Agents are embedded directly into workflows to continuously handle operational tasks such as governance, search and generation engine (LLM) optimization, translation, and lifecycle management, work that typically requires significant ma
HrFlow.ai Secures 7 Million Dollars (Pre-Series A) to Become the Global Standard for Artificial Intelligence (AI) Applied to HR Data24.4.2026 01:40:00 CEST | Press release
PARIS, FR / ACCESS Newswire / April 23, 2026 / 1. Fundraising and Objectives HrFlow.ai, a pioneer in Artificial Intelligence applied to Human Resources data, announces its second fundraising round of $7M (pre-Series A) today. This financing brings the company's total capital raised to $10 million. This new capital injection is designed to accelerate the company's core mission: building the Data & AI infrastructure of the labor market. The round is led by 115K, La Banque Postale's venture capital fund, and EmergingTech Ventures (EmTech), alongside the company's existing investors including Xavier Niel (Free, Kima, Station F), Jean-Baptiste Rudelle (Criteo), Romain Niccoli (Pigment, Criteo), Franck Le Ouay (LIFEN, Criteo), Flavien Kulawik (KLB), Allen Penn (Uber), Dominique Vidal (Index Ventures), Thibaud Elzière (Hexa, Fotolia). Building on rigorous execution and proven capital efficiency since its first funding round of $2.3M in 2018, HrFlow.ai now generates a margin of approximately 2
Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance22.4.2026 16:00:00 CEST | Press release
Builds on December 2025 Content Licensing Patents and Carbon Credit Tokenization Grant; Strengthens IP Moat Across Data Valuation, Virtual Funding, and Tokenized Tax Prep PHILADELPHIA, PA / ACCESS Newswire / April 22, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the issuance of U.S. Patent No. 12,596,819 and Notices of Allowance on two additional U.S. patent applications. This milestone builds directly on the Company's December 2025 issuance of two foundational patents for blockchain-driven content licensing and tokenized monetization - further expanding its robust intellectual property portfolio headlined by the industry-defining Carbon Credit Tokenization Patent. Key Highlights for Investors One newly issued patent and two Notices of Allowance extend protection across three high-value platforms: AI-validated d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom